Revance Therapeutics reported $71.07M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Abbvie ABBV:US $ 32521M 2673M
Aerie Pharmaceuticals AERI:US $ 115.29M 9.7M
Bristol Myers Squibb BMY:US $ 22821M 953M
Cara Therapeutics CARA:US $ 18.3M 680K
Coherus Biosciences CHRS:US $ 153.75M 11.58M
Eli Lilly And LLY:US $ 13386M 1666.7M
Endo International Ordinary Shares ENDP:US $ 1376.14M 253.82M
Horizon Pharma HZNP:US $ 825.18M 61.39M
JAZZ PHA JAZZ:US $ 737.41M 71.89M
Merk MRK:US $ 22316M 1556M
Pacira Pharmaceuticals PCRX:US $ 305.07M 216.04M
Procter & Gamble PG:US $ 34401M 3626M
Revance Therapeutics RVNC:US $ 71.07M 3.78M
Supernus Pharmaceuticals SUPN:US $ 284.56M 30.82M
Teva Pharmaceutical Industries TEVA:US $ 11613M 586M